Beibei Du
Beibei Du, MD, PhD is an expert in Cardiology at Jilin University (China). Beibei Du has authored 62 publications, the most recent in 2026. SLR score: 142 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Surgery - Infectiology - Oncology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Du Beibei is an Associate Chief Physician, Associate Professor, and Master's Supervisor in the Department of Cardiology at the China-Japan Union Hospital of Jilin University. He holds a Doctor of Medicine degree, has completed postdoctoral research, and was a visiting scholar at the University of Toronto.
His main research areas are interventional cardiology and cardio-oncology. He specializes in interventional treatment of complex coronary artery lesions. He studied at Stanford University in the United States and the University of Toronto in Canada.
He is a Fellow of the American College of Cardiology (FACC); a member of the Complex Coronary Intervention Group of the Chinese Society of Cardiology(CSC), a member of the Chest Pain Committee of the Chinese Medical Doctor Association (CMDA), a member of the Cardiovascular Imaging Committee of the Chinese Research Hospital Association, a member of the Youth Committee of the Cardiovascular Branch of the Chinese Geriatrics Society, a member of the Youth Expert Committee of the Heart Failure Management Center of the Chronic Disease Center of the Chinese Center for Disease Control and Prevention (CDC).
As the first author and corresponding author, he has published 21 SCI papers in journals such as JACC Cardio-oncology, CMAJ, and JAHA; he has presided over two National Natural Science Foundation of China (NSFC) Youth Fund and General Program projects, and 12 other projects including the Jilin Provincial Natural Science Foundation General Program; and he has presented at more than 20 top domestic and international cardiovascular conferences (Euro PCR, Great Wall International Congress of Cardiology-ICC, and the Annual Meeting of the Chinese Society of Cardiology). He received the titles of Excellent Instructor of Jilin University Scientific Research Training Program, Excellent Individual of Jilin University Sino-Japanese Friendship Hospital, Bethune Benevolent Mentor, Bethune Outstanding Young Physician.
Organizations
Career arc: 2015 - 2026
Number : 62
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Intensive lipid-lowering therapy-related regression of a vulnerable plaque confirmed by serial optical coherence tomography: a case report. PMID 41835459 — stents, myocardial infarction, pain, tomography, phenotype, acute coronary syndrome, tomography, optical coherence, therapeutics, chest pain | Front Cardiovasc Med | 2026 | 0 |
| Highly suspected fulminant myocarditis induced by the immune checkpoint inhibitor tislelizumab: a case report with third-degree atrioventricular block and recurrent ventricular tachycardia. PMID 41768571 — tachycardia, ventricular, atrioventricular block, gallbladder, neoplasms, adenocarcinoma, biomarkers, signs and symptoms, immune checkpoint inhibitors, myocarditis, echocardiography, tachycardia, therapeutics, electrocardiography, intrahepatic cholangiocarcinoma | Front Cardiovasc Med | 2026 | 1 |
| Modified cardiometabolic index and the risk of new-onset chronic diseases: a nationwide prospective cohort study. PMID 41652488 — chronic disease, cohort studies | Diabetol Metab Syndr | 2026 | 0 |
| Frailty and cardiovascular disease: a bidirectional relationship with clinical implications. PMID 41282339 — aging, cardiovascular diseases, precision medicine, therapeutics, frailty | Front Cardiovasc Med | 2025 | 0 |
| A systematic review and meta-analysis on the efficacy and safety of finerenone in the progression of heart failure. PMID 41020003 — diabetes mellitus, kidney diseases, mortality, safety, hospitalization, heart failure, heart, kidney, therapeutics | Front Pharmacol | 2025 | 0 |
LeadR Networks
Main global connection map